Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BDTX 
Black Diamond Therapeutics Inc (BDTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: BDTX (3-star) is a STRONG-BUY. BUY since 31 days. Simulated Profits (21.85%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 103.87% | Avg. Invested days 39 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 234.00M USD | Price to earnings Ratio 16.44 | 1Y Target Price 9 |
Price to earnings Ratio 16.44 | 1Y Target Price 9 | ||
Volume (30-day avg) 4 | Beta 3.08 | 52 Weeks Range 1.20 - 4.45 | Updated Date 10/21/2025 |
52 Weeks Range 1.20 - 4.45 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.63% | Operating Margin (TTM) 10.93% |
Management Effectiveness
Return on Assets (TTM) 3.02% | Return on Equity (TTM) 11.85% |
Valuation
Trailing PE 16.44 | Forward PE 8.33 | Enterprise Value 90291590 | Price to Sales(TTM) 3.34 |
Enterprise Value 90291590 | Price to Sales(TTM) 3.34 | ||
Enterprise Value to Revenue 1.29 | Enterprise Value to EBITDA 17.88 | Shares Outstanding 56935279 | Shares Floating 39236378 |
Shares Outstanding 56935279 | Shares Floating 39236378 | ||
Percent Insiders 0.65 | Percent Institutions 78.79 |
Upturn AI SWOT
Black Diamond Therapeutics Inc
Company Overview
History and Background
Black Diamond Therapeutics, Inc. is a precision oncology medicine company discovering and developing MasterKey therapies. Founded in 2014, it went public in 2020. The company focuses on allosteric mutant oncogenes.
Core Business Areas
- Oncology Drug Development: Focuses on developing small molecule therapeutics that selectively block the activity of mutated oncogenes.
Leadership and Structure
David Epstein serves as President and CEO. The company has a board of directors with expertise in biotech and pharmaceuticals.
Top Products and Market Share
Key Offerings
- BDTX-1535: A next generation MasterKey inhibitor of EGFR for patients with non-small cell lung cancer (NSCLC) and other solid tumors that harbor certain EGFR mutations. Currently in Phase 1/2 clinical trials. Competitors include other EGFR inhibitors from companies like AstraZeneca (AZN) and Novartis (NVS).
- BDTX-189: A MasterKey inhibitor of oncogenic NRG fusion proteins. Currently in preclinical stage of development. Competitors include other NRG fusion inhibitors.
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market, driven by increasing cancer incidence and advances in treatment options. Precision oncology, which targets specific genetic mutations, is a key trend.
Positioning
Black Diamond Therapeutics focuses on developing MasterKey therapies, which are designed to target a wide range of oncogenic mutations within a specific gene family. This approach aims to overcome resistance mechanisms and improve patient outcomes.
Total Addressable Market (TAM)
The TAM for precision oncology is substantial and expected to grow significantly. Black Diamond is positioned to capture a portion of this market by developing targeted therapies for specific oncogenic mutations.
Upturn SWOT Analysis
Strengths
- MasterKey inhibitor platform
- Focus on high-value oncology targets
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Reliance on clinical trial success
- Limited revenue
Opportunities
- Positive clinical trial data
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory approvals
Threats
- Clinical trial failures
- Competition from other drug developers
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- AZN
- NVS
- MRTX
Competitive Landscape
Black Diamond Therapeutics is a smaller player in the oncology market compared to larger pharmaceutical companies. Its competitive advantage lies in its MasterKey platform and focus on specific oncogenic mutations.
Growth Trajectory and Initiatives
Historical Growth: Since its IPO, Black Diamond has focused on advancing its clinical pipeline. Growth is tied to clinical data and partnerships.
Future Projections: Future growth depends on the success of ongoing and planned clinical trials. Analyst estimates vary.
Recent Initiatives: Advancing BDTX-1535 and BDTX-189 through clinical trials.
Summary
Black Diamond Therapeutics is an early-stage precision oncology company with a promising MasterKey platform. The company is focused on developing targeted therapies for specific oncogenic mutations. Clinical trial successes and strategic partnerships are crucial for its future growth and the firm needs to monitor their cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise. Financial data is sourced from publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Black Diamond Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-01-30 | CEO, President & Chairman Dr. Mark A. Velleca M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | |
Full time employees 24 | |||
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.